Published in J Infect Dis on September 01, 2010
Microbial translocation in HIV infection: causes, consequences and treatment opportunities. Nat Rev Microbiol (2012) 2.84
Impact of CD8+ T-cell activation on CD4+ T-cell recovery and mortality in HIV-infected Ugandans initiating antiretroviral therapy. AIDS (2011) 2.43
Microbial translocation across the GI tract. Annu Rev Immunol (2012) 2.30
Environmental enteropathy: critical implications of a poorly understood condition. Trends Mol Med (2012) 2.29
Enteropathies in the developing world: neglected effects on global health. Am J Trop Med Hyg (2012) 2.27
Microbial translocation, immune activation, and HIV disease. Trends Microbiol (2012) 2.07
HIV status, burden of comorbid disease, and biomarkers of inflammation, altered coagulation, and monocyte activation. Clin Infect Dis (2012) 1.83
Microbial translocation in the pathogenesis of HIV infection and AIDS. Clin Microbiol Rev (2013) 1.82
Altered CD4+ T cell homing to the gut impairs mucosal immune reconstitution in treated HIV-infected individuals. J Clin Invest (2011) 1.49
PD-1 blockade during chronic SIV infection reduces hyperimmune activation and microbial translocation in rhesus macaques. J Clin Invest (2012) 1.44
High T-cell immune activation and immune exhaustion among individuals with suboptimal CD4 recovery after 4 years of antiretroviral therapy in an African cohort. BMC Infect Dis (2011) 1.29
A plasma biomarker signature of immune activation in HIV patients on antiretroviral therapy. PLoS One (2012) 1.27
Evidence for polymicrobic flora translocating in peripheral blood of HIV-infected patients with poor immune response to antiretroviral therapy. PLoS One (2011) 1.21
Accelerated biological ageing in HIV-infected individuals in South Africa: a case-control study. AIDS (2013) 1.20
The kynurenine pathway of tryptophan catabolism, CD4+ T-cell recovery, and mortality among HIV-infected Ugandans initiating antiretroviral therapy. J Infect Dis (2014) 1.15
Increased microbial translocation in ≤ 180 days old perinatally human immunodeficiency virus-positive infants as compared with human immunodeficiency virus-exposed uninfected infants of similar age. Pediatr Infect Dis J (2011) 1.11
Immune activation and collateral damage in AIDS pathogenesis. Front Immunol (2013) 1.08
Is microbial translocation a cause or consequence of HIV disease progression? J Infect Dis (2011) 1.06
HIV-induced T-cell activation/exhaustion in rectal mucosa is controlled only partially by antiretroviral treatment. PLoS One (2012) 1.05
An exploratory trial of cyclooxygenase type 2 inhibitor in HIV-1 infection: downregulated immune activation and improved T cell-dependent vaccine responses. J Virol (2011) 1.05
Mechanisms of alcohol-mediated hepatotoxicity in human-immunodeficiency-virus-infected patients. World J Gastroenterol (2011) 1.02
Comparative impact of antiretroviral drugs on markers of inflammation and immune activation during the first two years of effective therapy for HIV-1 infection: an observational study. BMC Infect Dis (2014) 1.02
Serious Non-AIDS events: Immunopathogenesis and interventional strategies. AIDS Res Ther (2013) 1.01
Gut epithelial barrier and systemic inflammation during chronic HIV infection. AIDS (2015) 0.99
Kinetics of microbial translocation markers in patients on efavirenz or lopinavir/r based antiretroviral therapy. PLoS One (2013) 0.98
Role of intestinal mucosal integrity in HIV transmission to infants through breast-feeding: the BAN study. J Infect Dis (2013) 0.98
Innate and adaptive immune responses both contribute to pathological CD4 T cell activation in HIV-1 infected Ugandans. PLoS One (2011) 0.98
HIV-1 infection of human intestinal lamina propria CD4+ T cells in vitro is enhanced by exposure to commensal Escherichia coli. J Immunol (2012) 0.98
Mucosal immunity in human and simian immunodeficiency lentivirus infections. Mucosal Immunol (2013) 0.96
Immune activation is associated with increased gut microbial translocation in treatment-naive, HIV-infected children in a resource-limited setting. J Acquir Immune Defic Syndr (2014) 0.94
Systemic immune activation and microbial translocation in dual HIV/tuberculosis-infected subjects. J Infect Dis (2013) 0.94
Microbial translocation and microbiome dysbiosis in HIV-associated immune activation. Curr Opin HIV AIDS (2016) 0.94
The immunologic effects of mesalamine in treated HIV-infected individuals with incomplete CD4+ T cell recovery: a randomized crossover trial. PLoS One (2014) 0.92
Contribution of intestinal barrier damage, microbial translocation and HIV-1 infection status to an inflammaging signature. PLoS One (2014) 0.92
Relationship between microbial translocation and endothelial function in HIV infected patients. PLoS One (2012) 0.91
Increased gut microbial translocation in HIV-infected children persists in virologic responders and virologic failures after antiretroviral therapy. Pediatr Infect Dis J (2012) 0.90
Effect of micronutrient and probiotic fortified yogurt on immune-function of anti-retroviral therapy naive HIV patients. Nutrients (2011) 0.88
Inflammation, immune activation, and cardiovascular disease in HIV. AIDS (2016) 0.87
Variations in the heme oxygenase-1 microsatellite polymorphism are associated with plasma CD14 and viral load in HIV-infected African-Americans. Genes Immun (2011) 0.86
Pattern of microbial translocation in patients living with HIV-1 from Vietnam, Ethiopia and Sweden. J Int AIDS Soc (2014) 0.86
Gut epithelial barrier dysfunction in human immunodeficiency virus-hepatitis C virus coinfected patients: Influence on innate and acquired immunity. World J Gastroenterol (2016) 0.84
Gut Microbiota in HIV Infection: Implication for Disease Progression and Management. Gastroenterol Res Pract (2014) 0.83
Modulation of LPS-induced CD4+ T-cell activation and apoptosis by antioxidants in untreated asymptomatic HIV infected participants: an in vitro study. Clin Dev Immunol (2013) 0.83
Anti-retroviral therapy decreases but does not normalize indoleamine 2,3-dioxygenase activity in HIV-infected patients. PLoS One (2014) 0.83
Immune Reconstitution but Persistent Activation After 48 Weeks of Antiretroviral Therapy in Youth With Pre-Therapy CD4 >350 in ATN 061. J Acquir Immune Defic Syndr (2015) 0.83
Alcohol Use and Human Immunodeficiency Virus (HIV) Infection: Current Knowledge, Implications, and Future Directions. Alcohol Clin Exp Res (2016) 0.83
Effect of Probiotic Supplement on Cytokine Levels in HIV-Infected Individuals: A Preliminary Study. Nutrients (2015) 0.82
A 12 week longitudinal study of microbial translocation and systemic inflammation in undernourished HIV-infected Zambians initiating antiretroviral therapy. BMC Infect Dis (2014) 0.82
Microbial translocation: a marker of advanced HIV-1 infection and a predictor of treatment failure? J Infect Dis (2011) 0.82
Circulating biomarkers of immune activation distinguish viral suppression from nonsuppression in HAART-treated patients with advanced HIV-1 subtype C infection. Mediators Inflamm (2014) 0.82
Efavirenz is associated with higher bone mass in South African children with HIV. AIDS (2016) 0.82
Short communication: Evidence that microbial translocation occurs in HIV-infected children in the United Kingdom. AIDS Res Hum Retroviruses (2013) 0.81
Local and Long-Distance Calling: Conversations between the Gut Microbiota and Intra- and Extra-Gastrointestinal Tract Infections. Front Cell Infect Microbiol (2016) 0.80
Interleukin-37 Expression Is Increased in Chronic HIV-1-Infected Individuals and Is Associated with Inflammation and the Size of the Total Viral Reservoir. Mol Med (2015) 0.79
Novel relationships of markers of monocyte activation and endothelial dysfunction with pulmonary dysfunction in HIV-infected persons. AIDS (2016) 0.78
Monocytes from HIV-infected individuals show impaired cholesterol efflux and increased foam cell formation after transendothelial migration. AIDS (2015) 0.78
Cardiovascular Complications of HIV-Associated Immune Dysfunction. Cardiol Res Pract (2015) 0.78
CD14(+) macrophages that accumulate in the colon of African AIDS patients express pro-inflammatory cytokines and are responsive to lipopolysaccharide. BMC Infect Dis (2015) 0.77
Levels of circulating myeloid subpopulations and of heme oxygenase-1 do not predict CD4(+) T cell recovery after the initiation of antiretroviral therapy for HIV disease. AIDS Res Ther (2014) 0.77
HIV-associated changes in the enteric microbial community: potential role in loss of homeostasis and development of systemic inflammation. Curr Opin Infect Dis (2016) 0.76
Serum adenosine deaminase and total immunoglobulin G correlate with markers of immune activation and inversely with CD4 counts in asymptomatic, treatment-naive HIV infection. J Clin Immunol (2012) 0.76
Polymorphisms in the CD14 and TLR4 genes independently predict CD4+ T-cell recovery in HIV-infected individuals on antiretroviral therapy. AIDS (2016) 0.76
Attenuation of immune activation in an open-label clinical trial for HIV-AIDS using a polyherbal formulation. Virusdisease (2014) 0.75
Replication of CMV in the gut of HIV-infected individuals and epithelial barrier dysfunction. PLoS Pathog (2017) 0.75
Bone health in HIV-infected children, adolescents and young adults: a systematic review. J AIDS Clin Res (2014) 0.75
Genetic polymorphisms in the CD14 gene are associated with monocyte activation and carotid intima-media thickness in HIV-infected patients on antiretroviral therapy. Medicine (Baltimore) (2016) 0.75
Stimulation of PBMC and Monocyte-Derived Macrophages via Toll-Like Receptor Activates Innate Immune Pathways in HIV-Infected Patients on Virally Suppressive Combination Antiretroviral Therapy. Front Immunol (2016) 0.75
From Wasting to Obesity: The Contribution of Nutritional Status to Immune Activation in HIV Infection. J Infect Dis (2016) 0.75
Abnormal Bone Acquisition With Early-Life HIV Infection: Role of Immune Activation and Senescent Osteogenic Precursors. J Bone Miner Res (2016) 0.75
Impact of probiotic Saccharomyces boulardii on the gut microbiome composition in HIV-treated patients: A double-blind, randomised, placebo-controlled trial. PLoS One (2017) 0.75
Distortion of memory Vδ2 γδ T cells contributes to immune dysfunction in chronic HIV infection. Cell Mol Immunol (2014) 0.75
HIV and Obesity Comorbidity Increase Interleukin 6 but Not Soluble CD14 or D-Dimer. J Acquir Immune Defic Syndr (2017) 0.75
An automated genotyping system for analysis of HIV-1 and other microbial sequences. Bioinformatics (2005) 5.60
Towards an HIV cure: a global scientific strategy. Nat Rev Immunol (2012) 5.52
Use of dried whole blood spots to measure CD4+ lymphocyte counts in HIV-1-infected patients. Lancet (2003) 2.64
Molecular epidemiology: HIV-1 and HCV sequences from Libyan outbreak. Nature (2006) 2.61
Biological and technical variables affecting immunoassay recovery of cytokines from human serum and simulated vaginal fluid: a multicenter study. Anal Chem (2008) 2.12
A standardized framework for accurate, high-throughput genotyping of recombinant and non-recombinant viral sequences. Nucleic Acids Res (2009) 2.06
Horizontal versus familial transmission of Helicobacter pylori. PLoS Pathog (2008) 1.48
Macrophage polarization in health and disease. ScientificWorldJournal (2011) 1.46
A specific subtype C of human immunodeficiency virus type 1 circulates in Brazil. AIDS (2003) 1.45
Whole blood versus plasma spots for measurement of HIV-1 viral load in HIV-infected African patients. Lancet (2003) 1.43
Optimization of the oligonucleotide ligation assay, a rapid and inexpensive test for detection of HIV-1 drug resistance mutations, for non-North American variants. J Acquir Immune Defic Syndr (2008) 1.43
Monocyte-derived macrophages and myeloid cell lines as targets of HIV-1 replication and persistence. J Leukoc Biol (2006) 1.42
A pilot study of once-daily antiretroviral therapy integrated with tuberculosis directly observed therapy in a resource-limited setting. J Acquir Immune Defic Syndr (2004) 1.42
M1 and M2a polarization of human monocyte-derived macrophages inhibits HIV-1 replication by distinct mechanisms. J Immunol (2009) 1.39
Experience in implementing the OpenMRS medical record system to support HIV treatment in Rwanda. Stud Health Technol Inform (2007) 1.39
Association study of common genetic variants and HIV-1 acquisition in 6,300 infected cases and 7,200 controls. PLoS Pathog (2013) 1.33
Macrophage polarization and HIV-1 infection. J Leukoc Biol (2009) 1.32
Brief report: methods for collecting sexual behaviour information from South African adolescents--a comparison of paper versus personal digital assistant questionnaires. J Adolesc (2006) 1.28
Role of cytokines and chemokines in the regulation of innate immunity and HIV infection. Mol Immunol (2005) 1.28
Progression to AIDS in South Africa is associated with both reverting and compensatory viral mutations. PLoS One (2011) 1.24
"It's my blood": ethical complexities in the use, storage and export of biological samples: perspectives from South African research participants. BMC Med Ethics (2014) 1.23
Primary drug resistance in South Africa: data from 10 years of surveys. AIDS Res Hum Retroviruses (2012) 1.20
Amino acid starvation induces reactivation of silenced transgenes and latent HIV-1 provirus via down-regulation of histone deacetylase 4 (HDAC4). Proc Natl Acad Sci U S A (2012) 1.19
Genomic evolution and transmission of Helicobacter pylori in two South African families. Proc Natl Acad Sci U S A (2013) 1.18
TRIM22 inhibits HIV-1 transcription independently of its E3 ubiquitin ligase activity, Tat, and NF-kappaB-responsive long terminal repeat elements. J Virol (2011) 1.16
Mapping sites of positive selection and amino acid diversification in the HIV genome: an alternative approach to vaccine design? Genetics (2004) 1.15
In vitro hypersusceptibility of human immunodeficiency virus type 1 subtype C protease to lopinavir. Antimicrob Agents Chemother (2003) 1.14
Different epidemic potentials of the HIV-1B and C subtypes. J Mol Evol (2005) 1.12
Variability at human immunodeficiency virus type 1 subtype C protease cleavage sites: an indication of viral fitness? J Virol (2003) 1.10
Modeling HIV-1 drug resistance as episodic directional selection. PLoS Comput Biol (2012) 1.05
Long-lasting CCR5 internalization by antibodies in a subset of long-term nonprogressors: a possible protective effect against disease progression. Blood (2006) 1.03
Mosaic genomes of the six major primate lentivirus lineages revealed by phylogenetic analyses. J Virol (2003) 1.03
Inhibition of HIV-1 replication in monocyte-derived macrophages by Mycobacterium tuberculosis. J Infect Dis (2004) 1.03
Escape of monocyte-derived dendritic cells of HIV-1 infected individuals from natural killer cell-mediated lysis. AIDS (2003) 1.03
New players in cytokine control of HIV infection. Curr HIV/AIDS Rep (2008) 1.02
Persistent replication of severe acute respiratory syndrome coronavirus in human tubular kidney cells selects for adaptive mutations in the membrane protein. J Virol (2008) 1.00
Tracing the origin of Brazilian HTLV-1 as determined by analysis of host and viral genes. AIDS (2006) 0.99
Prevalence of HIV type-1 drug-associated mutations in pre-therapy patients in the Free State, South Africa. Antivir Ther (2009) 0.97
M1 polarization of human monocyte-derived macrophages restricts pre and postintegration steps of HIV-1 replication. AIDS (2013) 0.96
Increased sensitivity of SARS-coronavirus to a combination of human type I and type II interferons. Antivir Ther (2004) 0.94
A general strategy to endow natural fusion-protein-derived peptides with potent antiviral activity. PLoS One (2012) 0.94
QuantiFERON-TB GOLD ELISA assay for the detection of Mycobacterium tuberculosis-specific antigens in blood specimens of HIV-positive patients in a high-burden country. FEMS Immunol Med Microbiol (2009) 0.93
Prevalence of scientific misconduct among a group of researchers in Nigeria. Dev World Bioeth (2012) 0.92
Coronaviridae and SARS-associated coronavirus strain HSR1. Emerg Infect Dis (2004) 0.92
Southern African Treatment Resistance Network (SATuRN) RegaDB HIV drug resistance and clinical management database: supporting patient management, surveillance and research in southern Africa. Database (Oxford) (2014) 0.90
Novel evolutionary analyses of full-length HIV type 1 subtype C molecular clones from Cape Town, South Africa. AIDS Res Hum Retroviruses (2002) 0.90
Urokinase-urokinase receptor interaction mediates an inhibitory signal for HIV-1 replication. Proc Natl Acad Sci U S A (2002) 0.90
The puzzling role of CXCR4 in human immunodeficiency virus infection. Theranostics (2013) 0.90
HIV-1 infected lymphoid organs upregulate expression and release of the cleaved form of uPAR that modulates chemotaxis and virus expression. PLoS One (2013) 0.89
Cell surface-associated Tat modulates HIV-1 infection and spreading through a specific interaction with gp120 viral envelope protein. Blood (2004) 0.89
Tumor necrosis factor alpha, interleukin 2, and soluble interleukin 2 receptor levels in human immunodeficiency virus type 1-infected individuals receiving intermittent cycles of interleukin 2. AIDS Res Hum Retroviruses (2002) 0.89
The role of urokinase-type plasminogen activator (uPA)/uPA receptor in HIV-1 infection. J Leukoc Biol (2003) 0.89
Negative regulation of HIV-1 transcription by a heterodimeric NF-κB1/p50 and C-terminally truncated STAT5 complex. J Mol Biol (2011) 0.89
Naturally occurring C-terminally truncated STAT5 is a negative regulator of HIV-1 expression. Blood (2007) 0.88
Analysis of genes implicated in iron regulation in individuals presenting with primary iron overload. Hum Genet (2004) 0.88
HIV-1 Tat and heparan sulfate proteoglycan interaction: a novel mechanism of lymphocyte adhesion and migration across the endothelium. Blood (2009) 0.88
The intracellular detection of MIP-1beta enhances the capacity to detect IFN-gamma mediated HIV-1-specific CD8 T-cell responses in a flow cytometric setting providing a sensitive alternative to the ELISPOT. AIDS Res Ther (2008) 0.87
Broad spectrum inhibition of HIV-1 infection by sulfated K5 Escherichia coli polysaccharide derivatives. AIDS (2003) 0.87
Design and characterization of a peptide mimotope of the HIV-1 gp120 bridging sheet. Int J Mol Sci (2012) 0.87
IFN-gamma and IL-12 differentially regulate CC-chemokine secretion and CCR5 expression in human T lymphocytes. J Leukoc Biol (2002) 0.86
Preparing for phase II/III HIV vaccine trials in Africa. Microbes Infect (2005) 0.86
Characterization of HIV type 1 genetic diversity among South African participants enrolled in the AIDS Vaccine Integrated Project (AVIP) study. AIDS Res Hum Retroviruses (2010) 0.85
Retroviral interference on STAT activation in individuals coinfected with human T cell leukemia virus type 2 and HIV-1. J Immunol (2002) 0.85
Inhibition of HIV replication by the plasminogen activator is dependent on vitronectin-mediated cell adhesion. J Leukoc Biol (2007) 0.85
Urokinase plasminogen activator inhibits HIV virion release from macrophage-differentiated chronically infected cells via activation of RhoA and PKCε. PLoS One (2011) 0.84
Pertussis toxin (PTX) B subunit and the nontoxic PTX mutant PT9K/129G inhibit Tat-induced TGF-beta production by NK cells and TGF-beta-mediated NK cell apoptosis. J Immunol (2005) 0.84
Impaired CD4+ T-cell restoration in the small versus large intestine of HIV-1-positive South Africans receiving combination antiretroviral therapy. J Infect Dis (2013) 0.84
Quantifying antiretroviral risk in pregnancy. S Afr Med J (2007) 0.84
Differential dynamics of Epstein-Barr virus in individuals infected with human immunodeficiency virus-1 receiving intermittent interleukin-2 and antiretroviral therapy. Haematologica (2006) 0.83
BioAfrica's HIV-1 proteomics resource: combining protein data with bioinformatics tools. Retrovirology (2005) 0.83
Postgenomic up-regulation of CCL3L1 expression in HTLV-2-infected persons curtails HIV-1 replication. Blood (2006) 0.83
Restricted replication of primary HIV-1 isolates using both CCR5 and CXCR4 in Th2 but not in Th1 CD4(+) T cells. J Leukoc Biol (2002) 0.83
Implementing antiretroviral resistance testing in a primary health care HIV treatment programme in rural KwaZulu-Natal, South Africa: early experiences, achievements and challenges. BMC Health Serv Res (2014) 0.83
Hepatitis C virus (HCV) coinfection in a cohort of HIV positive long-term non-progressors: possible protective effect of infecting HCV genotype on HIV disease progression. J Clin Virol (2007) 0.83
Inhibition of herpes simplex virus types 1 and 2 in vitro infection by sulfated derivatives of Escherichia coli K5 polysaccharide. Antimicrob Agents Chemother (2008) 0.83
Treatment of non-alcoholic fatty liver disease: can we already face the epidemic? Acta Gastroenterol Belg (2013) 0.83
Imaging glucose metabolism in perfluorocarbon-perfused hepatocyte bioreactors using positron emission tomography. J Artif Organs (2009) 0.83
Cellular localization, invasion, and turnover are differently influenced by healthy and tumor-derived extracellular matrix. Tissue Eng Part A (2014) 0.82